Preventing contrast nephropathy in catheter laboratory

Heart

Volumn 93, Issue 6, 2007, Pages 654-655

  Fung, Jeffrey W H ^a   Szeto, Check C ^a   Yu, Cheuk M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CONTRAST MEDIUM; CREATININE; CYSTATIN C; ENDOTHELIN; IOPROMIDE; NONIONIC CONTRAST MEDIUM; SODIUM CHLORIDE; TAMM HORSFALL GLYCOPROTEIN; TRIMETAZIDINE; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CARDIOMYOPATHY; CELL PROTECTION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRAST NEPHROPATHY; CONTRAST RADIOGRAPHY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG SAFETY; EDITORIAL; GLUCOSE OXIDATION; HEART CATHETERIZATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY DISEASE; KIDNEY TUBULE NECROSIS; MEDICAL PRACTICE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ACETYLCYSTEINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; HEART CATHETERIZATION; HEMOFILTRATION; HUMANS; KIDNEY; KIDNEY DISEASES; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 34249294912     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.107714     Document Type: Editorial

References (15)

1. Alwall N, Erlanson P, Tornberg A. This clinical course of renal failure occurring after intravenous urography and/or retrograde pyelography; casuistics of 11 cases (including 7 deaths); on indications for and risks involved in the use of contrast media, including some remarks on the risk of aspiration biopsy of the kidney. Acta Med Scand 955, 152:163-73.
2. Chertow GM, Christiansen CL, Cleary DP. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 1995;155:1505-11.
3. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Cathet Cardiovasc Intervent 2001;52:409-16.
4. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
5. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
6. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243-8.
7. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
8. Fishbone S, Durham JH, Marzo K, et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 2004;15:251-60.
9. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-40.
10. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
11. Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-10.
12. Levey AS, Bosch JP, Lewis JB, for the Modification of Diet in Renal Disease Study Group, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
13. Davidson C, Stacul F, McCullough PA, Contrast medium use, et al. Am J Cardiol 2006;98:42K-58K.
14. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8.
15. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007;93:698-702.